Published on
December 13, 2022
- 21:05 GMT
Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint
- In new data from Phase 1/1b study, IVX-121 showed sustained immunologic response at six months; geometric mean titers (GMT) against RSV-A through day 180 persisting at 64-98% of the GMTs at day 28 in older adults - - First clinical evidence of potential …
Distribution channels:
Technology
...
